Partnerships

Our history of innovation is built on forming and fostering high-potential collaborations with industry and academic partners to accelerate the transformation of new scientific discoveries into meaningful clinical and medical advances.

Here's how we are partnering, today and in the future.

  • Scientific collaborations
  • Business development
  • Licensing
  • Advocacy and public affairs

You can find the full list of Kyowa Kirin’s Group partners here.

Transforming academic research into potential new therapies

Business development

Kyowa Kirin's vision is to contribute to human health and wellbeing worldwide through innovative drug discovery and global commercialization.

We fulfill this vision through diligent and continuous efforts to bring innovative pharmaceuticals to patients, utilizing our R&D knowledge and expertise as well as commercial capabilities. These capabilities are also available to help external partners enhance the value of their pharmaceutical innovations in the same therapeutic areas of focus: oncology, nephrology, immunology/allergy, and central nervous system (CNS).

Kyowa Kirin’s history in North America was shaped by business development deals and joint ventures of all sizes. We work with prospective partners to understand how our strengths match their needs, and we align financial terms and resources accordingly. Our custom alliance management approach helps to ensure that both partners can evaluate progress and optimize business results.

To start a dialogue, please email busdev.na@kyowakirin.com

Technology licensing

The potential of our antibody technology and expertise extends beyond our own pipeline. BioWa is a dedicated team of alliance managers who work to license the following technologies to other industry partners with promising drug candidates.

For POTELLIGENT®, Complegent® and AccretaMab® licensing inquiries, please complete this form.

POTELLIGENT®

The elimination of fucose from sugar chains on an antibody has forever changed the art and science of therapeutics. BioWa has harnessed the ability to create 100% fucose-free monoclonal antibodies, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC), the critical factor in anti-tumor activity.

This breakthrough antibody technology:

  • Dramatically enhances the potency and efficacy of antibodies. Clinical results with Potelligent®-enhanced antibodies are expected to show higher efficacy in human patients when compared with antibodies that have not been enhanced
  • Increases Fc receptor binding – overcomes the problem of low clinical responses due to genetic differences in the Fc receptor
  • Lowers the effective therapeutic dose of your antibodies — the potential to deliver much more with much less
  • Creates antibodies that are expected to be proven safe and well tolerated, with no immunogenic concerns
  • Requires no change in your current manufacturing process — BioWa’s proprietary technology works seamlessly with the systems and processes you already have in place
  • Reduces costs of goods (COGs)

COMPLEGENT®

COMPLEGENT® technology is a new technology developed by Kyowa Hakko Kogyo Co., Ltd. (now Kyowa Kirin Co., Ltd.). It enhances complement-dependent cytotoxicity (CDC), one of the major mechanisms of action of an antibody.

AccretaMab®

The AccretaMab® platform — antibodies created by using Potelligent® and Complegent® technologies — delivers the ultimate enhanced antibody therapeutics (with enhanced antibody-dependent cellular cytotoxicity [ADCC] and complement-dependent cytotoxicity [CDC]).

BioWa is the exclusive worldwide licensor of Potelligent® Technology, Complegent® Technology and the AccretaMab® platform.

References

POTELLIGENT®
COMPLEGENT®

Contact Us

*Required

Contact Form

  • For questions related to our products, please use the links provided under Our Medicines.

By clicking the Submit button, I authorize Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents to contact me by mail and/or email to provide information on products, programs, services, and disease-state information and/or utilize my information for market research or analytics. Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents will not utilize or distribute my personal information outside the above terms of consent.

Transforming academic research into potential new therapies

An example of our academic collaborations is our long-standing collaboration with the La Jolla Institute for Immunology, a world leader in cutting-edge molecular and cellular research. This extraordinarily successful and enduring research alliance is now entering its fourth decade. The arrangement marries Kyowa Kirin’s discovery and translational research capabilities with La Jolla Institute’s expertise in molecular and cellular discoveries — to identify the most promising targets to develop into potential new treatments. Over time, our combined efforts have produced experiments and clinical trials for a number of early-stage drug candidates targeting a range of immunologic conditions, including psoriasis, inflammatory bowel disease, and atopic dermatitis.

Situated in the same facility, we share an address as well as a passion for uncovering how the body’s immune system is engaged to fight disease. There is a constant flow of information between our teams, which work only steps apart. That proximity enables the exchange of information as data are gathered and a new understanding of cellular response begins to take shape. Prominent researchers at the Institute have been known to consult with our research managers and laboratory technicians on questions related to target identification and validation, and vice versa.

Kyowa Kirin is seeking to build on this success through more productive partnerships with academic institutions and research labs throughout North America to further our goals of discovery and development.